The filing secures the supply chain for Tenax's lead product candidate and extends the regulatory runway by nearly a decade, removing near-term termination risk.
Price Chart
Executive Summary
Tenax Therapeutics entered into a Supply Agreement with Orion Corporation for the manufacture and supply of its orally administered levosimendan product, and executed a Sixth Amendment to the License Agreement extending the regulatory approval deadline to December 31, 2035. The Supply Agreement includes cost-sharing for manufacturing scale-up and has a five-year initial term with automatic renewals. This is a routine operational and contractual update that secures the supply chain and extends the development timeline, but no financial terms were disclosed.
Key Facts
- Tenax and Orion entered into a Supply Agreement on June 29, 2026, for manufacture and supply of the oral levosimendan product.
- The Supply Agreement includes forecasting, ordering, delivery, quality, pricing, and cost-sharing provisions for scaling up manufacturing.
- Initial term of five years from first delivery, with automatic three-year renewals unless 24 months' notice of non-renewal is given.
- The Sixth Amendment extends the regulatory approval deadline for the product in the U.S. from an unspecified prior date to December 31, 2035.
- The Sixth Amendment also requires Tenax to comply with Orion's information and cybersecurity requirements.
- No financial terms (pricing, milestone payments, or deal value) were disclosed in the filing.
Financial Impact
No financial terms disclosed; the Supply Agreement includes cost-sharing for manufacturing scale-up but no dollar amounts were provided.
Risk Factors
- No financial terms disclosed — cost-sharing provisions could pressure cash runway if scale-up expenses are material.
- Regulatory approval still required by December 31, 2035; failure would trigger termination rights for either party.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-290661 |
| Document: d117070dex101.htm | 0001193125-26-290661 |
| Document: 0001193125-26-290661-index-headers.html | 0001193125-26-290661 |
| Document: 0001193125-26-290661-index.html | 0001193125-26-290661 |
| Document: 0001193125-26-290661.txt | 0001193125-26-290661 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | SC 13G/A | $1.62 | awaiting T+5 | — | $1.72 (+6.17%) |
Oct 15, 2026 12d ago | SC 13G/A | $1.36 $1.72 | ▲ +26.47% | ▲ +26.90% | $1.72 (+26.47%) |
Oct 13, 2026 14d ago | SC 13G/A | $1.60 $1.63 | ▲ +1.88% | ▲ +3.03% | $1.72 (+7.50%) |
Oct 9, 2026 18d ago | SC 13G/A | $1.83 $1.52 | ▼ −16.94% | ▼ −15.45% | $1.72 (−6.01%) |
Oct 8, 2026 19d ago | 8-K | $1.87 $1.36 | ▼ −27.27% | ▼ −25.30% | $1.72 (−8.02%) |
Sep 17, 2026 5w ago | Insider Cluster | $1.90 $1.81 | ▼ −4.74% | ▼ −6.01% | $1.72 (−9.47%) |
Sep 9, 2026 6w ago | 8-K | $2.13 $1.82 | ▼ −14.55% | ▼ −13.90% | $1.72 (−19.25%) |
Aug 29, 2026 8w ago | Press Release | $1.84 $2.05 | ▲ +11.20% | ▲ +11.34% | $1.72 (−6.52%) |
Aug 10, 2026 11w ago | 8-K | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.72 (+25.09%) |
Aug 10, 2026 11w ago | Press Release | $1.38 $1.71 | ▲ +24.36% | ▲ +24.41% | $1.72 (+25.09%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers